- Home
- CCSI vs ATYR Comparison
CCSI vs ATYR Comparison
Compare CCSI & ATYR Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- CCSI
- ATYR
- Stock Information
- Founded
- CCSI 2021
- ATYR 2005
- Country
- CCSI United States
- ATYR United States
- Employees
- CCSI N/A
- ATYR N/A
- Industry
- CCSI Retail: Computer Software & Peripheral Equipment
- ATYR Biotechnology: Biological Products (No Diagnostic Substances)
- Sector
- CCSI Technology
- ATYR Health Care
- Exchange
- CCSI Nasdaq
- ATYR Nasdaq
- Market Cap
- CCSI 450.6M
- ATYR 451.3M
- IPO Year
- CCSI N/A
- ATYR 2015
- Fundamental
- Price
- CCSI $23.84
- ATYR $5.30
- Analyst Decision
- CCSI Hold
- ATYR Strong Buy
- Analyst Count
- CCSI 5
- ATYR 6
- Target Price
- CCSI $27.20
- ATYR $20.20
- AVG Volume (30 Days)
- CCSI 156.2K
- ATYR 5.9M
- Earning Date
- CCSI 08-07-2025
- ATYR 08-07-2025
- Dividend Yield
- CCSI N/A
- ATYR N/A
- EPS Growth
- CCSI N/A
- ATYR N/A
- EPS
- CCSI 4.15
- ATYR N/A
- Revenue
- CCSI $349,595,000.00
- ATYR N/A
- Revenue This Year
- CCSI $1.18
- ATYR $551.06
- Revenue Next Year
- CCSI $0.56
- ATYR $1,874.58
- P/E Ratio
- CCSI $5.74
- ATYR N/A
- Revenue Growth
- CCSI N/A
- ATYR N/A
- 52 Week Low
- CCSI $17.84
- ATYR $1.67
- 52 Week High
- CCSI $32.10
- ATYR $7.29
- Technical
- Relative Strength Index (RSI)
- CCSI 65.78
- ATYR 49.97
- Support Level
- CCSI $19.42
- ATYR $4.47
- Resistance Level
- CCSI $21.79
- ATYR $5.74
- Average True Range (ATR)
- CCSI 0.83
- ATYR 0.62
- MACD
- CCSI 0.22
- ATYR -0.05
- Stochastic Oscillator
- CCSI 69.66
- ATYR 29.56
About CCSI Consensus Cloud Solutions Inc.
Consensus Cloud Solutions Inc is a provider of secure information delivery services with a scalable Software-as-a-Service SaaS platform. It is engaged in fax cloud business. The Company operates in USA, Canada, Ireland, and Other. Geographically, it derives a maximum revenue from the United States. The company's communication and digital signature solutions enable customers to securely and cooperatively access, exchange and use information across organizational, regional, and national boundaries.
About ATYR aTyr Pharma Inc. Common Stock
aTyr Pharma Inc is a biotherapeutics company engaged in the discovery and development of first-in-class medicines from its proprietary tRNA synthetase platform. The company has concentrated its research and development efforts on a newly discovered area of biology, the extracellular functionality and signaling pathways of tRNA synthetases. Its primary focus is efzofitimod, a clinical-stage product candidate which targets NRP2 to resolve chronic inflammation that can cause to fibrosis. Efzofitimod has a novel mechanism of action for potentially treating lung inflammation and fibrosis.